Organovo Holdings Issues 2,967,144 Additional Shares Through Warrant Exercises and At-The-Market Stock Sales, Raising ~$2.3M In Gross Proceeds, Bringing Total Outstanding Shares to 20,421,617

Author: Benzinga Newsdesk | March 06, 2025 09:52am

Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.

Posted In: ONVO